Biogen (BIIB) Tops Q3 EPS by 63c, Raises Guidance
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $212.50 -3.77%
Revenue Growth %: +4.3%
Financial Fact:
Amortization of acquired intangible assets: 99.7M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +4.3%
Financial Fact:
Amortization of acquired intangible assets: 99.7M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Biogen (NASDAQ: BIIB) reported Q3 EPS of $4.77, $0.63 better than the analyst estimate of $4.14. Revenue for the quarter came in at $2.51 billion versus the consensus estimate of $2.47 billion.
GUIDANCE:
Biogen sees FY2022 EPS of $16.50-$17.15, versus the consensus of $16.49. Biogen sees FY2022 revenue of $10-10.15 billion, versus the consensus of $10.01 billion.
For earnings history and earnings-related data on Biogen (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Casey's General Stores (CASY) Tops Q1 EPS by 69c
- ABM Industries (ABM) Reports In-Line Q3 EPS; raises guidance
- BMO Capital Starts American Eagle Outfitters (AEO) at Market Perform
Create E-mail Alert Related Categories
Earnings, Guidance, Hot EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
